Overview

• The NANOSPRESSO project aims to democratize precision medicine by enabling hospital pharmacies to produce low-cost, personalized gene and RNA therapies.
• The compact prototype integrates nucleic acid therapeutics with lipid nanoparticles in a cartridge-based microfluidic unit for onsite production.
• By decentralizing manufacturing to clinical settings, the device could address the treatment gap for rare diseases affecting 300 million people worldwide, including 36 million in the EU.
• Led by Prof. Raymond Schiffelers and Dr. Mariona Estapé Senti at UMC Utrecht, the research detailing the system is published in Frontiers in Science.
• The development team is collaborating with European regulators to refine safety, quality, and efficacy requirements ahead of real-world trials.